News and Announcements
SUDA Investor Initiative and Road Show Presentation
- Published August 14, 2015 3:45PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Perth, Australia, 14 August 2015
SUDA LTD (ASX: SUD), a leader in oro-mucosal drug delivery, today announces an initiative to broaden the Company’s investor base in Australia and Asia. This initiative includes raising awareness of SUDA with high-net-worth private investors as well as sophisticated investors.
As part of the initiative, Mr. Stephen Carter, Managing Director and CEO, presented at the Wholesale Investor – Asia-Pacific Emerging Company Expo 2015 in Singapore on 13 August 2015.
Mr. Carter and Mr. Nick Woolf, Chief Business Officer, are also meeting with institutional funds, family offices and retail brokers in Adelaide, Melbourne and Sydney on 18-21 August 2015. The management team will discuss recent milestone events and highlight key anticipated news flow for FY2016. The road show presentation follows.
To download the document, please click on the link below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
